united states , fail to either complete treatment or show a long-term sustained response to therapy .
as a result , we believe new safe and effective treatment options for hcv infection are needed .
telaprevir development program we are conducting three major phase 2b clinical trials of telaprevir .
prove 1 is ongoing in the united states and prove 2 is ongoing in european union , both in treatment-na efve patients .
prove 3 has commenced and is being conducted with patients in north america and the european union who did not achieve sustained viral response with previous interferon-based treatments .
prove 1 and prove 2 are fully enrolled , and we commenced patient enrollment in prove 3 in january 2007 .
prove 1 and prove 2 we expect that together , the prove 1 and prove 2 clinical trials will evaluate rates of sustained viral response , or svr , in approximately 580 treatment-na efve patients infected with genotype 1 hcv , including patients who will receive telaprevir and patients in the control arms .
svr is defined as undetectable viral levels 24 weeks after all treatment has ceased .
a description of each of the clinical trial arms for the prove 1 and prove 2 clinical trials , including the intended number of patients in each trial , is set forth in the following table : the prove 1 and prove 2 clinical trials together have the following four key objectives : 2022 to evaluate the optimal svr rate that can be achieved with telaprevir therapy in combination with peg-ifn and rbv ; 2022 to evaluate the optimal treatment duration for telaprevir combination therapy ; 2022 to evaluate the role of rbv in telaprevir-based therapy ; and 2022 to evaluate the safety of telaprevir in combination with peg-ifn and rbv .
in the prove 1 and prove 2 clinical trials , patients receive telaprevir in a tablet formulation at a dose of 750 mg every eight hours for 12 weeks .
the prove 1 clinical trial is double-blinded and placebo-controlled , and the prove 2 clinical trial is partially-blinded and placebo-controlled .
in december 2006 , we announced results from a planned interim safety and antiviral activity analysis that was conducted and reviewed by the independent data monitoring committee overseeing the prove 1 clinical trial .
as of the cut-off date of the interim analysis , a total of 250 patients had been enrolled in the prove 1 clinical trial and received at least one dose of telaprevir or placebo .
in the data reported , the patients in all three telaprevir-containing arms ( approximately 175 patients ) were pooled together and the results were compared to the results in the control arm of peg-ifn and rbv and placebo ( approximately 75 patients ) .
at the time of the data cut-off for the safety analysis , approximately 100 patients had completed 12 weeks on-study and more than 200 patients had completed eight weeks .
the most common adverse treatment regimen number of patients ( treatment na efve ) prove 1 number of patients ( treatment na efve ) prove 2 total .

Treatment Regimen
Number of Patients (treatment naïve) PROVE 1
Number of Patients (treatment naïve) PROVE 2
Total
12-week regimens of telaprevir in combination with peg-IFN and RBV
20
80
100
12-week regimens of telaprevir in combination with only peg-IFN
0
80
80
12-week regimens of telaprevir in combination with peg-IFN and RBV, followed by 12 weeks of therapy with peg-IFN and RBV
80
80
160
12-week regimens of telaprevir in combination with peg-IFN and RBV, followed by 36 weeks of therapy with peg-IFN and RBV
80
0
80
48-weeks of therapy with peg-IFN and RBV
80
80
160
Total
260
320
580

.

Question: Analyse this data from a financial earnings document. what was the percent of the total treatment regiment for prove1 for the 48-weeks of therapy with peg-ifn and rbv
Choices:
0.00769
30.76923
3.25
26.66667
0.30769
Correct choice index: 4